Key Points
-
C-RAF was the first of three RAF isoforms to be discovered over 20 years ago and its function and regulation have been studied in detail. RAF kinases have an important role in the regulation of cell growth, differentiation and survival and, in 2002, B-RAF was identified as a human oncogene that is mutated in approximately 7% of human cancers.
-
All three RAF isoforms — A-RAF, B-RAF and C-RAF — are protein kinases which are activated by the binding of small G proteins of the RAS family to the N-terminal region of the RAF proteins.
-
Phosphorylation is important in RAF regulation and, following its binding to RAS, C-RAF is recruited to the plasma membrane where dephosphorylation of negative regulatory sites and phosphorylation of positive regulatory sites cooperate to stimulate its kinase activity. For full activation, C-RAF must be phosphorylated on four sites and these sites seem to be the targets of at least three different kinases, which makes its activation a highly complex process.
-
By contrast, B-RAF only requires phosphorylation on two sites for activation, so its activation is relatively simple. The recently resolved crystal structure of B-RAF explains why phosphorylation of the activation segment is required and also explains how oncogenic mutations in the kinase domain result in a constitutive kinase activity.
-
The main downstream substrates of RAF kinases are MEK1 and MEK2 (mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) kinase-1 and -2). MEK1 and MEK2, in turn, phosphorylate and activate ERK1 and ERK2. We argue that
B-RAF is the main kinase that is responsible for coupling RAS to MEK, whereas C-RAF seems to have other, MEK-independent, functions, especially in the regulation of apoptosis. Other C-RAF effectors, such as apoptosis signal-regulating kinase-1 (ASK1) or BCL2-associated athanogene-1 (BAG1), are discussed.
-
As RAF proteins influence cell growth, survival and differentiation, the regulation of their biological functions is very complex and is modulated on a number of levels. They are activated by different extracellular stimuli and fine-tuning of their functions can be achieved by subtle modulation of their activity both temporally and spatially.
Abstract
Since their discovery over 20 years ago, the RAF proteins have been intensely studied. For most of that time, the focus of the field has been the C-RAF isoform and its role as an effector of the RAS proteins. However, a report that implicates B-RAF in human cancer has highlighted the importance of all members of this protein kinase family and recent studies have uncovered intriguing new data relating to their complex regulation and biological functions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rapp, U. R. et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl Acad. Sci. USA 80, 4218–4222 (1983). First report on the oncogene v- raf as a sequence that is acquired by the murine retrovirus 3611-MSV.
Jansen, H. W., Ruckert, B., Lurz, R. & Bister, K. Two unrelated cell-derived sequences in the genome of avian leukemia and carcinoma inducing retrovirus MH2. EMBO J. 2, 1969–1975 (1983). First report on the sequences of v- mil and c- mil , later shown to be the avian C-RAF homologue.
Jansen, H. W. et al. Homologous cell-derived oncogenes in avian carcinoma virus MH2 and murine sarcoma virus 3611. Nature 307, 281–284 (1984).
Moelling, K., Heimann, B., Beimling, P., Rapp, U. R. & Sander, T. Serine- and threonine-specific protein kinase activities of purified gag–mil and gag–raf proteins. Nature 312, 558–561 (1984).
Marais, R. & Marshall, C. J. Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv. 27, 101–125 (1996).
Barnier, J. V., Papin, C., Eychene, A., Lecoq, O. & Calothy, G. The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J. Biol. Chem. 270, 23381–23389 (1995).
Storm, S. M., Cleveland, J. L. & Rapp, U. R. Expression of raf family proto-oncogenes in normal mouse tissues. Oncogene 5, 345–351 (1990).
Luckett, J. C., Huser, M. B., Giagtzoglou, N., Brown, J. E. & Pritchard, C. A. Expression of the A-raf proto-oncogene in the normal adult and embryonic mouse. Cell Growth Differ. 11, 163–171 (2000).
Pritchard, C. A., Bolin, L., Slattery, R., Murray, R. & McMahon, M. Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. Curr. Biol. 6, 614–617 (1996).
Wojnowski, L. et al. Endothelial apoptosis in Braf-deficient mice. Nature Genet. 16, 293–297 (1997).
Wojnowski, L. et al. Craf-1 protein kinase is essential for mouse development. Mech. Dev. 76, 141–149 (1998).
Huser, M. et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J. 20, 1940–1951 (2001).
Mikula, M. et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J. 20, 1952–1962 (2001).
Robbins, D. J. et al. MAP kinases ERK1 and ERK2: pleiotropic enzymes in a ubiquitous signaling network. Adv. Cancer Res. 63, 93–116 (1994).
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002). Describes the first systematic genome-wide screen for oncogenes that was carried out by the Cancer Genome Project. The screen showed that B-RAF is mutated in approximately 7% of human cancers.
Allen, L. F., Sebolt-Leopold, J. & Meyer, M. B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 30, 105–116 (2003).
Patschinsky, T. & Bister, K. Structural analysis of normal and transforming mil(raf) proteins: effect of 5′-truncation on phosphorylation in vivo or in vitro. Oncogene 3, 357–364 (1988).
Marx, M. et al. A novel oncogene related to c-mil is transduced in chicken neuroretina cells induced to proliferate by infection with an avian lymphomatosis virus. EMBO J. 7, 3369–3373 (1988).
Wittinghofer, A. & Nassar, N. How Ras-related proteins talk to their effectors. Trends Biochem. Sci. 21, 488–491 (1996).
Hancock, J. F. Ras proteins: different signals from different locations. Nature Rev. Mol. Cell Biol. 4, 373–384 (2003).
Weber, C. K. et al. Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes. Oncogene 19, 169–176 (2000).
Tzivion, G. & Avruch, J. 14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation. J. Biol. Chem. 277, 3061–3064 (2002).
Dhillon, A. S. et al. Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol. Cell. Biol. 22, 3237–3246 (2002).
Light, Y., Paterson, H. & Marais, R. 14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity. Mol. Cell. Biol. 22, 4984–4996 (2002).
Clark, G. J. et al. 14-3-3ζ negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain. J. Biol. Chem. 272, 20990–20993 (1997).
Rommel, C. et al. Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1. Oncogene 12, 609–619 (1996).
Abraham, D. et al. Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J. Biol. Chem. 275, 22300–22304 (2000).
Jaumot, M. & Hancock, J. F. Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions. Oncogene 20, 3949–3958 (2001).
Ory, S., Zhou, M., Conrads, T. P., Veenstra, T. D. & Morrison, D. K. Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr. Biol. 13, 1356–1364 (2003).
Mischak, H. et al. Negative regulation of Raf-1 by phosphorylation of serine 621. Mol. Cell. Biol. 16, 5409–5418 (1996).
Marais, R. et al. Requirement of Ras–GTP–Raf complexes for activation of Raf-1 by protein kinase C. Science 280, 109–112 (1998).
Chiloeches, A. et al. Regulation of Ras·GTP loading and Ras–Raf association in neonatal rat ventricular myocytes by G protein-coupled receptor agonists and phorbol ester. Activation of the extracellular signal-regulated kinase cascade by phorbol ester is mediated by Ras. J. Biol. Chem. 274, 19762–19770 (1999).
King, A. J. et al. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 396, 180–183 (1998).
Chaudhary, A. et al. Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr. Biol. 10, 551–554 (2000).
Marais, R., Light, Y., Paterson, H. F. & Marshall, C. J. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 14, 3136–3145 (1995).
Marais, R., Light, Y., Paterson, H. F., Mason, C. S. & Marshall, C. J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem. 272, 4378–4383 (1997). Shows that whereas A-RAF and C-RAF require RAS binding and tyrosine phosphorylation by SRC to become fully activated, B-RAF does not require SRC for activation and is activated simply by RAS alone.
Wu, J. et al. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science 262, 1065–1069 (1993).
Sidovar, M. F. et al. Phosphorylation of serine 43 is not required for inhibition of c-Raf kinase by the cAMP-dependent protein kinase. J. Biol. Chem. 275, 28688–28694 (2000).
Dumaz, N., Light, Y. & Marais, R. Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms. Mol. Cell. Biol. 22, 3717–3728 (2002).
Dumaz, N. & Marais, R. Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J. Biol. Chem. 278, 29819–29823 (2003).
Zimmermann, S. & Moelling, K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286, 1741–1744 (1999).
Tzivion, G., Luo, Z. & Avruch, J. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 394, 88–92 (1998).
Yip-Schneider, M. T. et al. Regulation of the Raf-1 kinase domain by phosphorylation and 14-3-3 association. Biochem. J. 351, 151–159 (2000).
Fabian, J. R., Daar, I. O. & Morrison, D. K. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol. Cell. Biol. 13, 7170–7179 (1993).
Hekman, M. et al. Dynamic changes in C-Raf phosphorylation and 14-3-3 protein binding in response to growth factor stimulation: differential roles of 14-3-3 protein binding sites. J. Biol. Chem. 279, 14074–14086 (2004).
Mason, C. S. et al. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J. 18, 2137–2148 (1999). Together with references 33 and 44, describes the N-region and the important differences in regulation between C-RAF and B-RAF.
Chow, Y. H. et al. Functional mapping of the N-terminal regulatory domain in the human Raf-1 protein kinase. J. Biol. Chem. 270, 14100–14106 (1995).
King, A. J., Wireman, R. S., Hamilton, M. & Marshall, M. S. Phosphorylation site specificity of the Pak-mediated regulation of Raf-1 and cooperativity with Src. FEBS Lett. 497, 6–14 (2001).
Tilbrook, P. A., Colley, S. M., McCarthy, D. J., Marais, R. & Klinken, S. P. Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells. Arch. Biochem. Biophys. 396, 128–132 (2001).
Tran, N. H. & Frost, J. A. Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition. J. Biol. Chem. 278, 11221–11226 (2003).
Oehrl, W., Rubio, I. & Wetzker, R. Serine 338 phosphorylation is dispensable for activation of c-Raf1. J. Biol. Chem. 278, 17819–17826 (2003).
Sun, H., King, A. J., Diaz, H. B. & Marshall, M. S. Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak. Curr. Biol. 10, 281–284 (2000).
Zang, M., Hayne, C. & Luo, Z. Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1. J. Biol. Chem. 277, 4395–4405 (2002).
Chiloeches, A., Mason, C. S. & Marais, R. S338 phosphorylation of Raf-1 is independent of phosphatidylinositol 3-kinase and Pak3. Mol. Cell. Biol. 21, 2423–2434 (2001).
Zang, M. et al. Microtubule integrity regulates Pak leading to Ras-independent activation of Raf-1. Insights into mechanisms of Raf-1 activation. J. Biol. Chem. 276, 25157–25165 (2001).
Sutor, S. L., Vroman, B. T., Armstrong, E. A., Abraham, R. T. & Karnitz, L. M. A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates c-Raf and A-Raf. J. Biol. Chem. 274, 7002–7010 (1999).
Chong, H., Lee, J. & Guan, K. L. Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J. 20, 3716–3727 (2001).
Zhang, B. H. & Guan, K. L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 19, 5429–5439 (2000). Describes the identification of the two phsophorylation sites in the activation-segment of the B-RAF kinase domain that are required for its activation and therefore reveals the positive regulation of B-RAF by phosphorylation.
Wan, P. T. et al. Mechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855–867 (2004). Describes the solved crystal structure of B-RAF. First description of the structure of the B-RAF kinase domain. Provides insight into how B-RAF is regulated and why the mutations in cancer are activating.
Ikenoue, T. et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res. 63, 8132–8137 (2003).
Li, S. & Sedivy, J. M. Raf-1 protein kinase activates the NF-κB transcription factor by dissociating the cytoplasmic NF-κB–IκB complex. Proc. Natl Acad. Sci. USA 90, 9247–9251 (1993).
Janosch, P. et al. Characterization of IκB kinases. IκB-α is not phosphorylated by Raf-1 or protein kinase C isozymes, but is a casein kinase II substrate. J. Biol. Chem. 271, 13868–13874 (1996).
Baumann, B. et al. Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proc. Natl Acad. Sci. USA 97, 4615–4620 (2000).
Galaktionov, K., Jessus, C. & Beach, D. Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev. 9, 1046–1058 (1995).
Wang, S., Ghosh, R. N. & Chellappan, S. P. Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Mol. Cell. Biol. 18, 7487–7498 (1998).
Wang, H. G., Rapp, U. R. & Reed, J. C. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87, 629–638 (1996).
Wang, H. G., Takayama, S., Rapp, U. R. & Reed, J. C. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc. Natl Acad. Sci. USA 93, 7063–7068 (1996).
Troppmair, J. & Rapp, U. R. Raf and the road to cell survival: a tale of bad spells, ring bearers and detours. Biochem. Pharmacol. 66, 1341–1345 (2003).
Chen, J., Fujii, K., Zhang, L., Roberts, T. & Fu, H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism. Proc. Natl Acad. Sci. USA 98, 7783–7788 (2001).
Karasarides, M. et al. B-RAF is therapeutic target in melanoma. Oncogene 23, 6292–6298 (2004).
Houben, R. et al. Constitutive activation of the Ras–Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog. 3, 6 (2004).
Papin, C., Denouel, A., Calothy, G. & Eychene, A. Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system. Oncogene 12, 2213–2221 (1996).
Jaiswal, R. K., Moodie, S. A., Wolfman, A. & Landreth, G. E. The mitogen-activated protein kinase cascade is activated by B-Raf in response to nerve growth factor through interaction with p21ras. Mol. Cell. Biol. 14, 6944–6953 (1994).
Catling, A. D., Reuter, C. W., Cox, M. E., Parsons, S. J. & Weber, M. J. Partial purification of a mitogen-activated protein kinase kinase activator from bovine brain. Identification as B-Raf or a B-Raf-associated activity. J. Biol. Chem. 269, 30014–30021 (1994).
Moodie, S. A., Paris, M. J., Kolch, W. & Wolfman, A. Association of MEK1 with p21ras·GMPPNP is dependent on B-Raf. Mol. Cell. Biol. 14, 7153–7162 (1994).
Pritchard, C. A., Samuels, M. L., Bosch, E. & McMahon, M. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol. Cell. Biol. 15, 6430–6442 (1995). Shows that the individual RAF isoforms differ in their ability to activate MEK in cells and therefore differ in their biological function. In this study, B-RAF is identified as the RAF isoform that activates MEK with the highest efficiency.
Wojnowski, L., Stancato, L. F., Larner, A. C., Rapp, U. R. & Zimmer, A. Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis. Mech. Dev. 91, 97–104 (2000).
Mercer, K. et al. ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf. Oncogene 21, 347–355 (2002).
Marshall, C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179–185 (1995).
Weber, J. D., Raben, D. M., Phillips, P. J. & Baldassare, J. J. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem. J. 326, 61–68 (1997).
Woods, D. et al. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17, 5598–5611 (1997).
Kerkhoff, E. & Rapp, U. R. High-intensity Raf signals convert mitotic cell cycling into cellular growth. Cancer Res. 58, 1636–1640 (1998). References 81 and 82 show that the strength and duration of RAF kinase signalling is relevant for the biological outcome.
Kao, S., Jaiswal, R. K., Kolch, W. & Landreth, G. E. Identification of the mechanisms regulating the differential activation of the MAPK cascade by epidermal growth factor and nerve growth factor in PC12 cells. J. Biol. Chem. 276, 18169–18177 (2001).
Corbit, K. C. et al. Different protein kinase C isoforms determine growth factor specificity in neuronal cells. Mol. Cell. Biol. 20, 5392–5403 (2000).
Bogoyevitch, M. A., Marshall, C. J. & Sugden, P. H. Hypertrophic agonists stimulate the activities of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes. J. Biol. Chem. 270, 26303–26310 (1995).
Alavi, A., Hood, J. D., Frausto, R., Stupack, D. G. & Cheresh, D. A. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301, 94–96 (2003).
Guan, K. L. et al. Negative regulation of the serine/threonine kinase B-Raf by Akt. J. Biol. Chem. 275, 27354–27359 (2000).
Morrison, D. K. KSR: a MAPK scaffold of the Ras pathway? J. Cell Sci. 114, 1609–1612 (2001).
Morrison, D. K. & Davis, R. J. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu. Rev. Cell. Dev. Biol. 19, 91–118 (2003).
Pouyssegur, J., Volmat, V. & Lenormand, P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem. Pharmacol. 64, 755–763 (2002).
Anselmo, A. N., Bumeister, R., Thomas, J. M. & White, M. A. Critical contribution of linker proteins to Raf kinase activation. J. Biol. Chem. 277, 5940–5943 (2002).
Denouel-Galy, A. et al. Murine Ksr interacts with MEK and inhibits Ras-induced transformation. Curr. Biol. 8, 46–55 (1998).
Lanigan, T. M. et al. Human homologue of Drosophila CNK interacts with Ras effector proteins Raf and Rlf. FASEB J. 17, 2048–2060 (2003).
Li, W., Han, M. & Guan, K. L. The leucine-rich repeat protein SUR-8 enhances MAP kinase activation and forms a complex with Ras and Raf. Genes Dev. 14, 895–900 (2000).
Bonner, T. I. et al. Structure and biological activity of human homologs of the raf/mil oncogene. Mol. Cell. Biol. 5, 1400–1407 (1985).
Huebner, K. et al. Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human. Proc. Natl Acad. Sci. USA 83, 3934–3938 (1986).
Beck, T. W., Huleihel, M., Gunnell, M., Bonner, T. I. & Rapp, U. R. The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. Nucleic Acids Res. 15, 595–609 (1987).
Ikawa, S. et al. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol. Cell. Biol. 8, 2651–2654 (1988).
Kumar, R. et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res. 9, 3362–3368 (2003).
Acknowledgements
We would like to thank M. Garnett and the other members of the Signal Transduction Team for their helpful discussions. This work is funded by The Institute of Cancer Research, Cancer Research UK and The Biotechnology and Biological Sciences Research Council.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- HOMOLOGUES
-
Genes (or their products) that are descended from a common ancestral gene.
- SMALL G PROTEINS
-
Small proteins such as RAS that mediate signalling by binding and hydrolysing GTP. The GTP-bound form is active. It interacts with and activates several effector proteins that mediate downstream signalling events. The GDP-bound form is inactive.
- PARALOGUE
-
Genes or gene families that originated from a common ancestral sequence by a duplication event, and have since followed distinct lineages. Orthologues are from the same lineage of a family (for example, A-RAF, B-RAF and C-RAF). Paralogues and orthologues are homologues.
- CYSTEINE-RICH DOMAIN
-
(CRD). A zinc-finger-like structure located in CR1 of RAF proteins. It forms a secondary binding site for RAS, but binds in a GTP-independent manner. This region also interacts with 14-3-3 proteins and lipids.
- INNER LEAFLET
-
A lipid layer that faces the inside of the cell.
- 14-3-3
-
Adaptor/scaffold proteins that form homo- and heterodimers. They bind, through specialized phosphorylated peptide motifs, to various proteins that are involved in signal transduction and cell-cycle control.
- ADAPTOR PROTEINS
-
Proteins that augment cellular responses by recruiting other proteins to a complex. They usually contain several protein–protein interaction domains.
- TPA
-
(12,13-tetradecanoyl phorbol acetate). Also known as phorbol myristoyl acetate, this is the most commonly used phorbol ester. Phorbol esters are polycyclic esters that are isolated from croton oil. They are potent co-carcinogens or tumour promoters because they mimic diacylglycerol and thereby irreversibly activate protein kinase C.
- G-PROTEIN-COUPLED RECEPTOR
-
A seven-helix transmembrane-spanning cell-surface receptor that signals through heterotrimeric GTP-binding and -hydrolysing G proteins to stimulate or inhibit the activity of a downstream enzyme.
- HETEROTRIMERIC G PROTEIN
-
A protein complex of three proteins (Gα, Gβ and Gγ). Whereas Gβ and Gγ form a tight complex, Gα is part of the complex in its inactive, GDP-bound, form but dissociates in its active, GTP-bound, form. Both Gα and Gβγ can transmit downstream signals after activation.
- RHO-FAMILY GTPases
-
Ras-related GTPases involved in controlling the polymerization of actin.
- DOMINANT NEGATIVE
-
A defective protein that retains interaction capabilities and so distorts or competes with normal proteins.
- INTEGRINS
-
A large family of heterodimeric transmembrane proteins that function as receptors for cell-adhesion molecules.
- ACTIVATION SEGMENT
-
A region in protein kinases that lies between the invariant DFG and APE motifs and that in many, but not all, kinases is the site of regulatory phosphorylation events. This is often referred to as the 'activation loop', although it sometimes does not form a loop.
- GLYCINE-RICH LOOP
-
A conserved glycine-rich region that is located in the amino-terminal part of protein kinase domains. It is identified by the consensus motif Gly-X-Gly-X-X-Gly (where X represents any amino acid) and functions as a flexible loop that anchors the phosphates of ATP into the catalytic cleft.
- VENTRICULAR MYOCYTES
-
Cells derived from heart ventricles. These cells have limited proliferative potential and are used in models of biological responses to ischaemia/reperfusion, and to study hypertrophy (cell growth without division).
- ENDOTHELIAL CELLS
-
Thin, flattened cells of mesoblastic origin that are arranged in a single layer. They line the blood vessels and some body cavities, such as those of the heart.
Rights and permissions
About this article
Cite this article
Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5, 875–885 (2004). https://doi.org/10.1038/nrm1498
Issue Date:
DOI: https://doi.org/10.1038/nrm1498